JAK2 V617F mutation is not involved in thromboembolism in IBD

Inflammatory Bowel Diseases

Volumn 14, Issue 11, 2008, Pages 1606-1607

  Karimi, Ouafae ^a   Crusius, J Bart A ^a   Coucoutsi, Constantina ^b   Heijmans, Roel ^a   Sambuelli, Alicia M ^c   Salvador Pena A ^a   Koutroubakis, Ioannis E ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c HOSPITAL DE GASTROENTEROLOGÍA DR CARLOS BONORINO UDAONDO   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; HEMOGLOBIN; JANUS KINASE 2;

ADOLESCENT; ADULT; AGED; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; GENE FREQUENCY; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; LETTER; LEUKOCYTOSIS; PATHOGENESIS; PRIORITY JOURNAL; THROMBOEMBOLISM; ULCERATIVE COLITIS; ARGENTINA; FEMALE; GENE EXPRESSION REGULATION; GENETICS; INCIDENCE; MALE; MIDDLE AGED; MUTATION; PRESCHOOL CHILD; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; ARGENTINA; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; THROMBOEMBOLISM; YOUNG ADULT;

EID: 58049111376     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20471     Document Type: Letter

References (8)

1. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
2. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDG-FRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-1214.
3. Boissinot M, Garand R, Hamidou M, et al. The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS). Blood. 2006;108:1781-1782.
4. De Stefano V, Fiorini A, Rossi E, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost. 2007;5:708-714.
5. Miehsler W, Reinisch W, Valic E, et al. Is in.ammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut. 2004;53:542-548.
6. Koutroubakis IE, Sfiridaki A, Tsiolakidou G, et al. Genetic risk factors in patients with inflammatory bowel disease and vascular complications: case-control study. Inflamm Bowel Dis. 2007;13:410-415.
7. Burova E, Vassilenko K, Dorosh V, et al. Interferon gamma-dependent transactivation of epidermal growth factor receptor. FEBS Lett. 2007;581:1475-1480.
8. Rothlisberger B, Huber A, Bargetzi M, et al. JAK2 exon 12 mutation in JAK2V617F-negative polycythemia vera. Leuk Lymphoma.